Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

Similar articles for PubMed (Select 25163170)

1.

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.

Lin CY, Chi HC, Shih KC, Zhou J, Hsiao NW, Tang CY.

Int J Data Min Bioinform. 2014;9(3):305-20.

PMID:
25163170
2.

Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV).

Hitaoka S, Matoba H, Harada M, Yoshida T, Tsuji D, Hirokawa T, Itoh K, Chuman H.

J Chem Inf Model. 2011 Oct 24;51(10):2706-16. doi: 10.1021/ci2002395. Epub 2011 Sep 13.

PMID:
21870866
3.

In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.

Liu H, Yao X, Wang C, Han J.

Mol Pharm. 2010 Jun 7;7(3):894-904. doi: 10.1021/mp100041b.

PMID:
20420444
4.

QSAR analyses on avian influenza virus neuraminidase inhibitors using CoMFA, CoMSIA, and HQSAR.

Zheng M, Yu K, Liu H, Luo X, Chen K, Zhu W, Jiang H.

J Comput Aided Mol Des. 2006 Sep;20(9):549-66. Epub 2006 Nov 11.

PMID:
17103017
5.

Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.

Magano J.

Chem Rev. 2009 Sep;109(9):4398-438. doi: 10.1021/cr800449m. Review. No abstract available.

PMID:
19537777
6.

Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.

McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC, Varghese JN.

J Virol. 1998 Mar;72(3):2456-62.

7.

[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].

Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F.

Pathol Biol (Paris). 2010 Apr;58(2):e69-78. doi: 10.1016/j.patbio.2010.01.011. Epub 2010 Mar 19. Review. French.

PMID:
20303677
8.

Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase.

Wang Y, Wu D, Yu D, Wang Z, Tian L, Wang Y, Han W, Fang X.

J Mol Model. 2012 Aug;18(8):3445-53. doi: 10.1007/s00894-011-1349-0. Epub 2012 Jan 27.

PMID:
22278046
9.

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.

Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ.

Nature. 2008 Jun 26;453(7199):1258-61. doi: 10.1038/nature06956. Epub 2008 May 14.

PMID:
18480754
10.

Molecular docking, 3D-QSAR studies, and in silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors.

Zhang J, Shan Y, Pan X, Wang C, Xu W, He L.

Chem Biol Drug Des. 2011 Oct;78(4):709-17. doi: 10.1111/j.1747-0285.2011.01179.x. Epub 2011 Sep 6.

PMID:
21752201
11.

Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.

Wang SQ, Du QS, Huang RB, Zhang DW, Chou KC.

Biochem Biophys Res Commun. 2009 Aug 28;386(3):432-6. doi: 10.1016/j.bbrc.2009.06.016. Epub 2009 Jun 10.

PMID:
19523442
12.

Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.

Wei DQ, Du QS, Sun H, Chou KC.

Biochem Biophys Res Commun. 2006 Jun 9;344(3):1048-55. Epub 2006 Apr 19.

PMID:
16647045
13.

Study on molecular mechanism and 3D-QSAR of influenza neuraminidase inhibitors.

Yi X, Guo Z, Chu FM.

Bioorg Med Chem. 2003 Apr 3;11(7):1465-74.

PMID:
12628672
14.

Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.

Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF.

PLoS Pathog. 2011 Oct;7(10):e1002249. doi: 10.1371/journal.ppat.1002249. Epub 2011 Oct 20.

15.

Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.

Wang YT, Chan CH, Su ZY, Chen CL.

Biophys Chem. 2010 Mar;147(1-2):74-80. doi: 10.1016/j.bpc.2009.12.002. Epub 2009 Dec 6.

PMID:
20045243
16.

Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.

Zhang Q, Yang J, Liang K, Feng L, Li S, Wan J, Xu X, Yang G, Liu D, Yang S.

J Chem Inf Model. 2008 Sep;48(9):1802-12. doi: 10.1021/ci800041k. Epub 2008 Aug 16.

PMID:
18707092
17.

Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).

Du QS, Huang RB, Wei YT, Du LQ, Chou KC.

J Comput Chem. 2008 Jan 30;29(2):211-9.

PMID:
17559075
18.

Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.

Kim JH, Resende R, Wennekes T, Chen HM, Bance N, Buchini S, Watts AG, Pilling P, Streltsov VA, Petric M, Liggins R, Barrett S, McKimm-Breschkin JL, Niikura M, Withers SG.

Science. 2013 Apr 5;340(6128):71-5. doi: 10.1126/science.1232552. Epub 2013 Feb 21.

19.

Neuraminidase inhibitors for preventing and treating influenza in children.

Matheson NJ, Symmonds-Abrahams M, Sheikh A, Shepperd S, Harnden A.

Cochrane Database Syst Rev. 2003;(3):CD002744. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD002744.

PMID:
12917931
20.

Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.

Du QS, Gao J, Wei YT, Du LQ, Wang SQ, Huang RB.

J Chem Inf Model. 2012 Apr 23;52(4):996-1004. doi: 10.1021/ci300066y. Epub 2012 Apr 13.

PMID:
22480344
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk